Page 104 - Read Online

Rastogi. Hepatoma Res 2020;6:47 I http://dx.doi.org/10.20517/2394-5079.2020.35 Page 15 of 17

review. Liver Transpl Surg 1999;5:91-5.
46. Lin CC, Yang HM. Fibrolamellar carcinoma: a concise review. Arch Pathol Lab Med 2018;142:1141-5.
47. Van Eyken P, Sciot R, Brock P, Casteels-Van Daele M, Ramaekers FC, et al. Abundant expression of cytokeratin 7 in fibrolamellar
carcinoma of the liver. Histopathology 1990;17:101-7.
48. Cheuk-Lam Lo R. An update on the histological subtypes ofhepatocellular carcinoma. Hepatoma Res 2019;5:41.
49. International consensus group for hepatocellular neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the
international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
50. Agni RM. Diagnostic histopathology of hepatocellular carcinoma: a case-based review. Semin Diagn Pathol 2017;34:126-37.
51. Bosman FTCF, Hruban RH, Theise ND. World Health Organization classification oftumours: pathology and genetics of tumours of the
digestive system. Lyon, France: IARC Press; 2010.
52. Torbenson MS. Morphologic Subtypes of hepatocellular carcinoma. Gastroenterol Clin North Am 2017;46:365-91.
53. Ang CS, Kelley RL, Choti MA, Cosgrove DP, ChouJF, et al. Clinicopathologic characteristics and survivaloutcomes of patients with
fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013;6:3-9.
54. Fujii T, Zen Y, Harada K, Harada K, Niwa HN, Masuda S, et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of
scirrhous hepatocellular carcinoma-human and cell culture study. Hum Pathol 2008;39:1185-96.
55. Lee JH, Choi MS, Gwak GY, Gwak GY,Lee JH, et al. Clinicopathologic characteristics and long-term prognosis of scirrhous
hepatocellular carcinoma. Dig Dis Sci 2012;57:1698-707.
56. Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and treatment of hepatocellular carcinoma in 2016: standards and developments. Visc
Med 2016;32:116-120.
57. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, et al. Long-term results of hepatic resection for hepatocellular carcinoma originating
from the noncirrhotic liver. Arch Surg 2004;139:320-5.
58. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop
without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
59. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzéet E, et al. Histological subtypes of hepatocellular carcinoma are related to gene
mutations and molecular tumour classification. J Hepatol 2017;67:727-38.
60. Okuda K, Nakashima T, Kojiro M, Kondo Y, Wada K. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology
1989;97:140-6.
61. Shimada M, Rikimaru T, Sugimachi K, Hamatsu T, Yamashita Y, et al. The importance of hepatic resection for hepatocellular carcinoma
originating from nonfibrotic liver. J AmColl Surg 2000;191:531-7.
62. Grando-Lemaire V, Guettier C, Chevret S, M Beaugrand, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West:
epidemiological factors and histopathology of the non-tumorous liver. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. J
Hepatol 1999;31:508-13.
63. Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and
histopathologic analysis of 80 French cases. Hepatology 2000;32:200-4.
64. van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen HJ, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic
livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol 2016;28:352-9.
65. Pittman ME, Brunt EM. Anatomic pathology of hepatocellular carcinoma: histopathology using classic and new diagnostic tools. Clin
Liver Dis 2015;19:239-59.
66. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic
alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 2013;44: 750-8.
67. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, et al. A single-center surgical experience of 122 patients with single and multiple
hepatocellular adenomas. Gastroenterology 2009;137:1698-705.
68. Bioulac-Sage P, Laumonier H, Couchy G, Bail BL, Cunha A, et al. Hepatocellular adenoma management and phenotypic classification:
the Bordeaux experience. Hepatology 2009;50:481-9.
69. Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and
malignancy. Ann Surg Oncol 2009;16:640-8.
70. Roncalli M, Sciarra A, Tommaso LD. Benign hepatocellular nodules of healthy liver: Focal nodular hyperplasia and hepatocellular
adenoma. Clin Mol Hepatol 2016;22:199-211.
71. Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, et al. Clinicopathological features of focal nodular hyperplasia-like
nodules in 130 cirrhotic explant livers. Am J Gastroenterol 2006;101:2341-6.
72. Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, et al. Over-expression of glutamine synthetase in focal nodular hyperplasia:
a novel easy diagnostic tool in surgical pathology. Liver Int 2009;29:459-65.
73. Nakanuma Y, Sripa B, Vatanasapt B, Leong A, Ponchon T, et al: Intrahepatic cholangiocarcinoma. In: Hamilton SR, Aaltonen LA, editors.
WHO Classification of Tumors, Pathology and Genetics Tumors of the Digestive System. Lyon: IARC Press; 2000. pp. 173-80.
74. Suriawinata AA, Thung SN. Malignant liver tumors. Clin Liver Dis 2002;6:527-54, ix.
75. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology
2004;39:798-803.
76. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence
of both hepatocyte and bile duct differentiation. Mod Pathol 2010;23:1180-90.
77. Ross HM, Daniel HD, Vivekanandan P, Kannangai R, Yeh MM, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol